The incidence of Kaposi sarcoma is increasing among Black men and decreasing among White men in the United States, a study suggests.
None of the patients had grade 3 or higher acute radiation toxicity.
In a first-in-human trial of patients with solid tumors, a MYC inhibitor appeared tolerable and enabled nearly half of evaluable patients to maintain stable disease.
There are several factors that may increase the risk of thoracic soft tissue sarcoma in patients with a history of breast cancer.
COVID-19 vaccination is safe for cancer patients receiving immune checkpoint inhibitors and should not interrupt therapy, according to researchers.
The incidence of invasive breast cancer among childhood cancer survivors decreased from the 1970s to the 1990s.
Phase 3 data do not support adding ifosfamide to adjuvant methotrexate, doxorubicin, and cisplatin in patients with high-grade osteosarcoma.
Researchers sought to increase the rate of serious illness conversations between clinicians and patients with cancer.
The approvals were based on data from the LIBRETTO-001 trial.
Cabazitaxel demonstrated antitumor activity in patients with previously treated, advanced dedifferentiated liposarcoma in a phase 2 trial.
Cancer patients with HIV do not receive curative or palliative care in the same way as their HIV-negative peers.
Adding trabectedin to doxorubicin doubled the median progression-free survival.
Dinutuximab plus GM-CSF produced a low disease control rate that did not meet a historical benchmark.
There was no significant difference in overall survival between patients who received actinomycin-D and those who received carboplatin.
Survival outcomes for patients on the EURAMOS-1 trial were not affected by race/ethnicity or poverty exposure.
Ifosfamide improved event-free and overall survival.
Twenty-three percent of adolescents and young adults with sarcoma who used opioids during treatment had new persistent opioid use after treatment.
In a phase 2 study, researchers are investigating the combination of cryoablation and dual checkpoint inhibition.
Lurbinectedin produced an overall response rate of 14.3% and a disease control rate of 57.1%.
High-dose treosulfan plus melphalan followed by autologous stem cell reinfusion did not improve event-free or overall survival.